Company news
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) news
60 Degrees Pharmaceuticals, Inc. news releases on 6ix. Latest, Oct 6, 2026: 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data…
Press releases & updates
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
October 5, 2026
60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
October 1, 2026
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
October 1, 2026
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
September 30, 2026
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
August 17, 2026
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
July 30, 2026
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
July 29, 2026
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
July 7, 2026
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
July 1, 2026
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
June 11, 2026
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
May 26, 2026
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
May 15, 2026
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
April 14, 2026
60 Degrees Pharmaceuticals Announces 2025 Annual Results
March 30, 2026
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
March 17, 2026
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
March 10, 2026
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
February 2, 2026
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
January 28, 2026
60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention
January 22, 2026
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
January 15, 2026
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
December 29, 2025
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
December 11, 2025
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
November 21, 2025
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
November 13, 2025
60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
October 15, 2025
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
October 9, 2025
Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22
October 2, 2025
60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
August 21, 2025
60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
August 19, 2025
60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
August 13, 2025
60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria
July 17, 2025
60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering
July 16, 2025
60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering
July 15, 2025
60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion
July 15, 2025
60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025
July 14, 2025
60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
June 4, 2025
Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals
June 3, 2025
60 Degrees Pharmaceuticals Announces First Quarter 2025 Results
May 15, 2025
Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey
April 22, 2025
Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21
April 10, 2025
Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health
April 8, 2025
60 Degrees Pharmaceuticals Announces 2024 Annual Results
March 28, 2025
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split
February 20, 2025
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
February 10, 2025
60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
February 4, 2025
60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
January 28, 2025
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
January 27, 2025
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
January 7, 2025